At a glance
- Originator Meiji Seika Kaisha
- Developer Meiji Seika Kaisha; Nonindustrial source
- Class Immunotherapies
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Transplant rejection